Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, Bocchia M. Defina M, et al. Among authors: ippoliti m. Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19. Cancer. 2012. PMID: 22517301 Free article.
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT, Crupi R, Tozzuoli D, Trawinska MM, Defina M, Martinelli G, Lauria F. Bocchia M, et al. Among authors: ippoliti m. Leukemia. 2008 Feb;22(2):426-8. doi: 10.1038/sj.leu.2404893. Epub 2007 Aug 9. Leukemia. 2008. PMID: 17690698 No abstract available.
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G. Breccia M, et al. Among authors: ippoliti m. Br J Haematol. 2010 Jul;150(2):240-2. doi: 10.1111/j.1365-2141.2010.08187.x. Epub 2010 Mar 19. Br J Haematol. 2010. PMID: 20346015 Free article. No abstract available.
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R. Zaja F, et al. Among authors: ippoliti m. Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9. Haematologica. 2008. PMID: 18403395 Free article.
61 results